Field Medical has announced the successful closing of US$40 million in Series A financing. The round includes US$20 million in new capital and the conversion of US$20 million in seed-round debt. Participants include several leading strategics, venture capital firms and family offices, with multiple seed investors reinvesting—which, according to a company press release, underscores “strong confidence” in Field Medical’s initial focus on ventricular tachycardia (VT) and the broader versatility of its pulsed field ablation (PFA) technology.
The funding will support the completion of two pilot studies—VCAS for VT and Field PULSE for atrial fibrillation (AF)—as well as continued development of Field Medical’s commercial PFA system and operational scaleup in preparation for VERITAS, the company’s pivotal trial focused on VT.
“This financing is a pivotal milestone as we advance in redefining how electrophysiologists approach ablation therapy,” said Steven Mickelsen, founder and chief executive officer (CEO) of Field Medical. “With the support of our investors, we are accelerating the development of the FieldForce ablation system, building on early clinical evidence, and moving closer to our commercial goal of expanding access to next-generation PFA solutions for cardiac ablation.”
“We are encouraged by the strong support and confidence from both new investors and our reinvesting seed-round investor base,” added Oskar Dadason, Field Medical’s chief financial officer. “This funding enables us to execute our strategic plan with speed and focus as we transition from early-stage innovation into commercial readiness.”
In its recent release, Field Medical says it is developing transformative technology for the treatment of all cardiac arrhythmias, including VT and AF.
The FieldForce ablation system—featuring “the first built-for-purpose, contact force focal PFA catheter”—enables an instantaneous ablation workflow, with therapy delivered “in a fraction of a second”. The company claims that recent results from the VCAS (VT) and PULSE (AF) pilot studies demonstrate the system’s versatility. Powered by FieldBending, the company’s proprietary technology that delivers brief, high-intensity electric fields, the system is positioned as “the single, advanced solution for treating a full spectrum of cardiac arrhythmias”.
